Eyepoint, Inc.
A biopharmaceutical company that treats serious eye diseases with tiny, long-lasting implants placed in the eye. Its Durasert technology delivers steady doses of medication over months, powering products like YUTIQ for uveitis and DEXYCU for inflammation after cataract surgery. Founded in 1987 and long known as pSivida Corporation, it renamed itself EyePoint in 2018 after buying Icon Bioscience — the name a nod to its single-minded focus on the eye.
Bought 25.47M · Sold 700.0K
Bought 4.79M · Sold 60.0K
Granted 227.4K · Sold 190.0K
Granted 1.03M · Bought 186.4K · Sold 75.0K
Granted 311.0K · Bought 6.5K
Granted 150.4K · Bought 40.0K
Granted 199.6K
Granted 119.2K
Granted 54.7K · Sold 23.1K
Sold 2.91M
Sold 2.91M
Granted 164.5K · Sold 45.0K
Granted 347.6K · Sold 121.3K
Granted 162.6K · Sold 73.2K
Granted 6.0K · Bought 32.5K
Granted 17.4K · Bought 40.0K
Granted 60.3K · Bought 1.0K · Sold 46.0K
Granted 36.7K · Sold 34.9K
Granted 8.2K · Bought 5.0K
Granted 12.5K
Bought 10.0K
Granted 7.4K · Bought 2.6K
Granted 23.6K · Bought 17.0K
Granted 6.7K
Granted 4.0K
Granted 56.2K · Sold 52.6K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| EW Healthcare Partners, L.P. +3 co-filers10% owner, See footnotes 1 and 3, 10% owner · 20 transactions | — | 14.68Mas of Sep 2023 | — | 25.47M | 700.0K |
| Chen Bihua +2 co-filersFormer 10% Owner · 25 transactions | — | 8.27M | — | 4.79M | 60.0K |
| Ashton PaulPresident & CEO, Director · 26 transactions | — | 467.5Kas of Mar 2016 | 227.4K | — | 190.0K |
| Lurker NancyDirector · 46 transactions | — | 421.2K | 1.03M | 186.4K | 75.0K |
| Duker Jay S.President and CEO, Director · 42 transactions | — | 356.8K | 311.0K | 6.5K | — |
| Elston GeorgeChief Financial Officer · 41 transactions | — | 240.3K | 150.4K | 40.0K | — |
| Mazzo David JDirector · 6 transactions | — | 200.1Kas of Oct 2019 | 199.6K | — | — |
| Rogers Michael WDirector · 3 transactions | — | 119.2Kas of Jun 2019 | 119.2K | — | — |
| Freedman LoriVP Corp. Affairs, GC and Sec · 11 transactions | — | 100.9Kas of Jun 2014 | 54.7K | — | 23.1K |
| Liu YeDirector · 4 transactions | — | 100.2Kas of Jan 2024 | — | — | 2.91M |
| Ocumension TherapeuticsDirector · 3 transactions | — | 100.2Kas of Jan 2024 | — | — | 2.91M |
| Ross Leonard SSee Remarks · 21 transactions | — | 92.0Kas of Jun 2019 | 164.5K | — | 45.0K |
| Paggiarino Dario A.Chief Medical Officer · 65 transactions | — | 74.2Kas of Mar 2024 | 347.6K | — | 121.3K |
| Jones David ScottSVP & Chief Commercial Officer · 40 transactions | — | 48.6Kas of Feb 2024 | 162.6K | — | 73.2K |
| Zaderej Karen L.Director · 8 transactions | — | 38.5Kas of Jul 2025 | 6.0K | 32.5K | — |
| Landis John B.Director · 5 transactions | — | 21.4Kas of Jan 2025 | 17.4K | 40.0K | — |
| Pine Michael CraigChief Corp Dev.&Strat. Officer · 6 transactions | — | 13.7Kas of Jan 2024 | 60.3K | 1.0K | 46.0K |
| Guyer David RDirector · 12 transactions | — | 13.5Kas of Jul 2024 | 36.7K | — | 34.9K |
| Ando GoranDirector · 4 transactions | — | 13.2Kas of Aug 2024 | 8.2K | 5.0K | — |
| Barry James JDirector · 1 transaction | — | 12.5Kas of May 2018 | 12.5K | — | — |
| Hopper PaulDirector · 2 transactions | — | 10.0Kas of Oct 2012 | — | 10.0K | — |
| Dicicco Wendy FDirector · 4 transactions | — | 10.0Kas of Aug 2024 | 7.4K | 2.6K | — |
| Godshall Douglas EvanDirector · 5 transactions | — | 8.0Kas of Jun 2021 | 23.6K | 17.0K | — |
| Peterson KristineDirector · 1 transaction | — | 6.7Kas of Jun 2019 | 6.7K | — | — |
| Adamis Anthony PDirector · 2 transactions | — | 4.0Kas of Jun 2024 | 4.0K | — | — |
| Ribeiro RamiroChief Medical Officer · 11 transactions | — | 2.4K | 56.2K | — | 52.6K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: +23.36M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.